×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Bladder

Arlene Weintraub
Immunotherapies known as checkpoint inhibitors are so promising in bladder cancer that many patients want them as first treatments — before they’ve been proven in that setting.
Virginia Powers, Ph.D.
Keytruda (pembrolizumab) produced better overall survival (OS) rates than chemotherapy for patients with recurrent, advanced urothelial carcinoma.
Danielle Bucco
Jonathan E. Rosenberg, M.D., discusses the implications of the new treatment guidelines for muscle-invasive bladder cancer.
Jeffrey Holzbeierlein, M.D.
Jeffrey Holzbeierlein, M.D., University of Kansas Medical Center, discusses how important it was that a multidisciplinary team came together to create the non-metastatic muscle-invasive bladder cancer guidelines.
 
Johnathan E. Rosenberg, M.D.
Jonathan E. Rosenberg, M.D., medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.
Diane Zipursky Quale
Diane Zipursky Quale, co-founder of the Bladder Cancer Advocacy Network, discusses the importance of patients discussing their treatment options with their physician before undergoing surgery.
Jason Harris
For patients with cisplatin-ineligible advanced urothelial cancer, frontline treatment with Keytruda (pembrolizumab) showed long-lasting response, according to updated phase 2 results from the KEYNOTE-052 trial.
Shannon Connelly
Imfinzi (durvalumab) may change the treatment paradigm for some patients with urothelial carcinoma.
Ariela Katz
When used as a neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC), split-dose of gemcitabine and cisplatin has a beneficial response and a high safety profile, according to a study presented at the 2017 American Urological Association Annual Meeting.
Katie Kosko
Combined modality treatment (CMT) could be considered a first course of treatment for patients with muscle-invasive bladder cancer, according to the authors of a recent study published in the International Journal of Radiation Oncology.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable